Figure 1. Overall survival of (a) all patients (n = 27), (b) patients treated with radiotherapy combined concurrently with weekly chemotherapy of cisplatin plus 5-FU (CF group, n = 14) or nedaplatin plus 5-FU (NF group, n = 13), (c) patients achieved complete/partial remission (CR/PR, n = 19) or stable/progressive disease (SD/PD, n = 8), and (d) patients with Eastern Cooperative Oncology Group Performance Status Scale (ECOG PS) of 0–1 (n = 17) or 2 (n = 10).